摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7-O,O-demethylenepodophyllotoxin | 1174-97-6

中文名称
——
中文别名
——
英文名称
6,7-O,O-demethylenepodophyllotoxin
英文别名
3',4'-demethylenepodophyllotoxin;6,7-O-Demethylen-podophyllotoxin;(3aR,4R,9R,9aR)-4,6,7-trihydroxy-9-(3,4,5-trimethoxyphenyl)-3a,4,9,9a-tetrahydro-3H-benzo[f]isobenzofuran-1-one;(3aR,4R,9R,9aR)-4,6,7-trihydroxy-9-(3,4,5-trimethoxyphenyl)-3a,4,9,9a-tetrahydro-3H-benzo[f][2]benzofuran-1-one
6,7-O,O-demethylenepodophyllotoxin化学式
CAS
1174-97-6
化学式
C21H22O8
mdl
——
分子量
402.401
InChiKey
AIEQNTGIFXFNRB-BTINSWFASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    222-224 °C
  • 沸点:
    652.7±55.0 °C(Predicted)
  • 密度:
    1.396±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    115
  • 氢给体数:
    3
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and Quantitative Structure–Activity Relationship (QSAR) Study of Novel 4-Acyloxypodophyllotoxin Derivatives Modified in the A and C Rings as Insecticidal Agents
    摘要:
    In continuation of our program aimed at the discovery and development of natural-product-based insecticidal agents, we have synthesized three series of novel 4-acyloxy compounds derived from podophyllotoxin modified in the A and C rings, which is isolated as the main secondary metabolite from the roots and rhizomes of Podophyllum hexandrum. Their insecticidal activity was preliminarily evaluated against the pre-third-instar larvae of Mythimna separata in vivo. Compound 9g displayed the best promising insecticidal activity. It revealed that cleavage of the 6,7-methylenedioxy group of podophyllotoxin will lead to a less active compound and that the C-4 position of podophyllotoxin was the important modification location. A quantitative structure activity relationship (QSAR) model was developed by genetic algorithm combined with multiple linear regression (GA-MLR). For this model, the squared correlation coefficient (R-2) is 0.914, the leave-one-out cross-validation correlation coefficient (Q(LOO)(2)) is 0.881, and the root-mean-square error (RMSE) is 0.024. Five descriptors, BEHm2, Mor14v, Wap, G1v, and RDF020e, are likely to influence the biological activity of these compounds. Among them, two important ones are BEHm2 and Mor14v. This study will pave the way for further design, structural modification, and development of podophyllotoxin derivatives as insecticidal agents.
    DOI:
    10.1021/jf305011n
  • 作为产物:
    描述:
    鬼臼毒素三氯化硼calcium carbonate 作用下, 以 二氯甲烷丙酮 为溶剂, 反应 2.25h, 以80%的产率得到6,7-O,O-demethylenepodophyllotoxin
    参考文献:
    名称:
    在A环中修饰的鬼臼毒素类似物的合成和细胞毒性。
    摘要:
    已经制备了几种缺乏亚甲二氧基或环木脂素骨架的A环功能不同的鬼臼毒素衍生物,并评估了它们对四种肿瘤细胞系(P-388,A-549,HT-29和MEL-28)的细胞毒活性)。他们中的大多数保持其细胞毒性在microM水平。
    DOI:
    10.1016/s0223-5234(02)00007-7
点击查看最新优质反应信息

文献信息

  • Synthesis of podophyllotoxin A-ring pyridazine analogue
    作者:Emmanuel Bertounesque、Thierry Imbert、Claude Monneret
    DOI:10.1016/0040-4020(96)00862-9
    日期:1996.11
    Podophyllotoxin A-ring pyridazine analogue 3 has been constructed in nine steps from (−)-podophyllotoxin. The Stille reaction was exploited to generate the key intermediate 4.
    鬼臼毒素A环哒嗪类似物3已从(-)-鬼臼毒素开始九步构建。利用Stille反应生成关键中间体4。
  • Biosynthesis of podophyllum lignans—i. cinnamic acid precursors of podophyllotoxin in podophyllum hexandrum
    作者:David E. Jackson、Paul M. Dewick
    DOI:10.1016/s0031-9422(00)82603-5
    日期:1984.1
  • In vivo immunosuppressive activity of some cyclolignans
    作者:Marina Gordaliza、MaAngeles Castro、JoséMa Miguel del Corral、MaLuisa López-Vázquez、Arturo San Feliciano、Glynn T. Faircloth
    DOI:10.1016/s0960-894x(97)10072-5
    日期:1997.11
    Several podophyllotoxin-related cyclolignans, either lacking the lactone ring or the methylenedioxy grouping, have been prepared and evaluated for their immunosuppressive (IMS) activity in the mouse allogeneic MLR in vitro test and in the in vivo techniques Graft vs Host Reaction (GVHR) and Skin Grafting (SG). The results obtained show that three cyclolignans fairly prevent splenomegaly in comparison with control animals and also promoted tolerance to grafting, being the first time that the in vivo LMS activity of cyclolignas is reported. (C) 1997 Elsevier Science Ltd.
  • Antitumor Agents. 164. Podophenazine, 2‘‘,3‘‘-Dichloropodophenazine, Benzopodophenazine, and Their 4β-<i>p</i>-Nitroaniline Derivatives as Novel DNA Topoisomerase II Inhibitors
    作者:Sung Jin Cho、Yoshiki Kashiwada、Kenneth F. Bastow、Yung-Chi Cheng、Kuo-Hsiung Lee
    DOI:10.1021/jm950548u
    日期:1996.1.1
    We report here the synthesis and biological evaluation of novel DNA topoisomerase II inhibitors, podophenazine (8), 2'',3''-dichloropodophenazine (9), and benzopodophenazine (10), and their 4 beta-p-nitroaniline derivatives 13-15. Among these, 4'-O-demethyl-4 beta-(4'''-nitroanilino)-4-desoxypodophenazine (13) and 4'-O-demethyl-2'',3''-dichloro-4 beta-(4'''-nitroanilino)-4-desoxypodophenazine (14) were found to inhibit KB cells at sub-micromolar concentrations (IC50 = 0.11 +/- 0.03 and 0.48 +/- 0.17 mu M, respectively). Against KB/7d cells (a pleiotrophic multiple drug-resistant subclone selected with etoposide which has reduced level of topoisomerase II), only compound 13 out of a target series maintained activity in the sub-micromolar concentration range with a IC50 value of 0.56 +/- 0.13 mu M. The differential toxicity ratio for 13 [IC50(KB/7d)/IC50(KB)] was similar to 5. Unlike etoposide and its congeners, compounds 13 and 14 were found to be weak inhibitors of the catalytic activity of topoisomerase II (IC100 = >100 and >150 mu M, respectively). In vitro protein-linked DNA complex formation assay revealed that 13 and 14, respectively, induced marginal response (13 at 1 mu M, 320.3 +/- 124.5 cpm; 13 at 50 mu M, 308.8 +/- 139.9 cpm; 13 at 100 mu M, 446.0 +/- 153.5 cpm) and no response (14 at 1 mu M, 104.9 +/- 52.6 cpm; 14 at 50 mu M, 103.3 +/- 42.6 cpm; 14 at 100 mu M, 101.4 +/- 35.2 cpm) compared to the enzyme control. On the basis of these results, we conclude that the mechanism of enzyme inhibition of these compounds is distinct from that of etoposide and its congeners. We are currently investigating the mechanism(s) of action of compounds 13 and 14 as well as synthesizing other derivatives in order to better characterize structure-activity relationships of this series of compounds.
  • Antitumor agents. 124. New 4.beta.-substituted aniline derivatives of 6,7-O,O-demethylene-4'-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II
    作者:Zhe-Qing Wang、Hong Hu、Hong-Xin Chen、Yung-Chi Cheng、Kuo Hsiung Lee
    DOI:10.1021/jm00083a010
    日期:1992.3
    A series of 6,7-O,O-demethylene-4'-O-demethyl-4-beta-(substituted anilino)-4-desoxypodophyllotoxins (18-23), 6,7-O,O-demethylene-6,7-O,O-dimethyl-4'-O-demethyl-4-beta-(substituted anilino)-4-desoxypodophyllotoxins (28-31), and their corresponding 4'-O-methyl analogues (12-17 and 24-27) have been synthesized and evaluated for their inhibitory activity against the human DNA topoisomerase II as well as for their activity in causing cellular protein-linked DNA breakage. Compounds 18-23 are 2-fold more potent than etoposide and compounds 12, 16, 17, 30, and 31 are as active as etoposide in their inhibition of the human DNA topoisomerase II. Compounds 19 and 20 and 29-31 are as active or more active than etoposide in causing protein-linked DNA breakage. These results indicate that a free C-4' hydroxy group is essential for the DNA breakage activity, and that the hydroxyl groups at C-6 and -7 positions may be involved in an interaction which is responsible for the inhibitory activity of DNA topoisomerase II. The maintenance of an intact methylene dioxy-type ring-A system would contribute to enhanced activity. In addition, the sterically less hindered substitution at C-6 and C-7 positions may be important for optimal interactions with DNA topoisomerase II. There is no correlation between the ability of these compounds to inhibit DNA topoisomerase II and their ability to cause protein-linked DNA breaks in cells. This may relate to the difference in uptake of these compounds. The better correlation was observed between the protein-linked DNA breaks and the cytotoxicity in KB cells of these compounds.
查看更多

同类化合物

鬼臼脂毒酮 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 苦鬼臼毒素 脱氧鬼臼毒素 磷酸依托泊甙 盾叶鬼臼素 澳白木脂素2 澳白木脂素1 替尼泊苷 托尼依托泊苷 去氧鬼臼毒素 克立米星C 他氟泊苷 丙氨酸,N-(羧基甲基)-(9CI) alpha-盾叶鬼臼素 alpha-依托泊苷 [(5R,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-8-氧代-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-5-基]丁酸酯 TOP-53二盐酸盐 NK-611盐酸盐 5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-(5R,5aR,8aR,9S)-呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5aH)-酮 4’-去甲鬼臼毒素 4’-去甲基表鬼臼毒素-Β-D-葡萄糖甙 4-{[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]氨基甲酰}苯基乙酸酯 4,6-O-苄叉-Β-D-葡萄糖甙鬼臼毒素 4'-去甲基表鬼臼毒素 4'-O-脱甲基-4-((4'-(1'-苯甲基哌啶基))氨基)-4-脱氧鬼臼毒 4 ’-去甲去氧鬼臼毒素 3-羟基-4H-吡喃-4-酮 3-氨基-N-[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]苯酰胺 2’-O-没食子酰基金丝桃甙 2(3H)-硫代酰苯,3-乙基二氢-3-(1-甲基乙基)-(9CI) 2'-氯依托泊苷 1-羟基-17-氧杂五环[6.6.5.0~2,7~.0~9,14~.0~15,19~]十九碳-2,4,6,9,11,13-六烯-16,18-二酮(non-preferredname) (8aR,9S)-9-[[(2R)-7,8-二羟基-2-(2-噻吩基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5S,5aS,8aR,9R)-5-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基-苯基)-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-8-酮 (5S,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-5-(4-羟基苯基)硫烷基-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二噁唑-8-酮 (5R,5aR,8aS,9S)-9-[(4-氨基苯基)氨基]-5-(4-羟基-3,5-二甲氧苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-6(5aH)-酮盐酸(1:1) (5R,5aR,8aR,9R)-9-羟基-10-甲氧基-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(4-甲氧基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(2-羟基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-8-羰基-9-(3,4,5-三甲氧苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基乙酸酯 (5R,5aR,8aR,9R)-5-(4-乙氧基-3,5-二甲氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-5-(3,5-二甲氧基-4-丙氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R)-5,8,8ab,9-四氢-5b-(3,4,5-三甲氧基苯基)呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5abH),9-二酮 (5-氯吡啶-3-基)丙酸甲酯 (3aS,4S,9R,9aR)-4-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基苯基)-6,7-二甲氧基-3a,4,9,9a-四氢-3H-萘并[3,2-c]呋喃-1-酮 (3aR,4S,9R,9aR)-4,6,7-三羟基-9-(4-羟基-3,5-二甲氧苯基)-3a,4,9,9a-四氢萘并[2,3-c]呋喃-1(3H)-酮 (1R,3aS,4R,6aR)-4-(1,3-苯并二氧戊环-4-基)-1-(1,3-苯并二氧戊环-5-基)-3,3a,4,6a-四氢-1H-呋喃并[3,4-c]呋喃-6-酮